蒲地蓝消炎口服液临床应用疗效的系统评价

Systematic Review of the Clinical Effectiveness of Pudilan Xiaoyan Oral Liquid

目的系统评价蒲地蓝消炎口服液治疗各种疾病的临床疗效及安全性。方法检索数据库Embase、PubMed、中国期刊全文数据库(CNKI)、万方科技数据库、中国生物医学文献数据库(CBM)和中文科技期刊全文数据库(VIP)有关蒲地蓝消炎口服液治疗各种疾病的临床试验研究(检索时间均从创建至2018年5月),对纳入的文献进行定量或定性的系统评价。结果共纳入85篇文献,研究的疾病涉及上呼吸道感染(22篇)、咽峡炎(15篇)、扁桃体炎(24篇),手足口病(17篇),口腔溃疡(7篇)。结果显示,与常规治疗措施相比,蒲地蓝消炎口服液可有效提高上呼吸道感染、咽峡炎、扁桃体炎、手足口病、口腔溃疡的总体有效性,缩短上呼吸道感染和扁桃体炎的退热时间。但尚无证据表明蒲地蓝消炎口服液在缩短咽峡炎的退热时间,以及在减少上呼吸道感染和咽峡炎不良反应事件发生率上与常规治疗有差异。结论蒲地蓝消炎口服液治疗各种疾病的有效性较好。但因纳入文献研究质量不齐,尚需更多大样本、更高质量的临床随机对照试验予以证实。

Objective To systematically evaluate the clinical efficacy and safety of Pudilan Xiaoyan Oral Liquid(PXOL)in the treatment of various diseases.Methods The clinical trial studies of PXOL for treating various diseases were retrieved from Embase,PubMed,National Knowledge Infrastructure(CNKI)of China,Wanfang Database,Chinese Biological Medicine Database(CMB),and Chongqing VIP Database(since their establishment to May 2018).The quantitative or qualitative systematic review were performed with included studies.Results A total of 85 articles were eligible,including 22 articles of upper respiratory infection(URI),15 articles of angina,24 articles of amygdalitis,17 articles of hand-foot-mouth disease and 7 articles of oral ulcer.The results of meta-analysis showed that,compared with routine therapy,PXOL could effectively improve the overall effectiveness of URI,angina,amygdalitis,hand-foot-mouth disease,and oral ulcer.Besides,it could shorten the antipyretic time of URI and amygdalitis.However,there was no evidence that POXL could shorten the antipyretic time of angina and the incidence of adverse events of URI and angina compared with routine therapy.Conclusion PXOL is effective in treating various diseases.However,due to the uneven quality of studies,clinical randomized controlled trials of larger sample sizes and higher quality are needed to confirm the results.